Breaking News

OSO Bio Invests In Aseptic Filling Suite

May 1, 2012

Adds Bosch equipment

OSO BioPharmaceuticals Manufacturing LLC is investing more than $5 million in equipment and infrastructural improvements that include a new Grade A aseptic filling suite for liquid, suspension and lyophilized products.

The rolling diaphragm pump-filling suite, manufactured by Bosch, comes equipped with optional rotary piston and peristaltic pumps. According to the company, it will function at 115% of the previous line’s capacity, increasing the speed and efficiency to deliver drug products to clients.

The new line has the ability to conduct non-destructive online weight tests for greater precision and yield, and its restricted access barrier system, according to the company, minimizes risk of cross-contamination and diminishes potential occupational exposure.

 “This state-of-the-art filling suite represents a substantial investment in the future – the future of OsoBio, as well as the futures of the pharmaceutical clients we serve,” said Milton Boyer, president. “It allows OsoBio to manufacture drugs in a better, smarter and faster manner, while ensuring high-quality product and the safety of patients and employees alike. This is an exciting new addition to OsoBio’s facility.”

The new line produces sterile liquid, suspension and lyophilized formulations in vial sizes ranging from 2cc to 100cc. The Bosch equipment includes: an RRU 3084/44 high-performance container washing machine, an HQL 4480S drying and sterilization tunnel, an FLC 3080 filling and closing machine, a GLT 4040 tray loader, and a TRL1030 tray loader. The new filling suite is expected to be fully validated and operational by late August.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks